2024-10-19 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis

**Company Overview:** Merck & Co., Inc., known as MSD outside the United States and Canada, is a global pharmaceutical company that develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** 70.52% for MRK, 136.97% for VOO.
* **Relative Divergence:** -66.45%, indicating MRK has underperformed VOO by 66.45% since the start of the period. This places it at the 18.6 percentile of its historical performance range.

**2. Recent Price Movement:**

* **Closing Price:** $109.75
* **5-day Moving Average:** $110.22
* **20-day Moving Average:** $111.88
* **60-day Moving Average:** $114.82

The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a possible short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 35.86, indicating a slightly oversold condition.
* **PPO:** 0.03, indicating a minor bullish momentum.
* **Delta_Previous_Relative_Divergence:** -14.64, implying a recent short-term bearish divergence.
* **Expected Return:** 0.0%, indicating no expected outperformance compared to S&P 500 (VOO) over the next 5 years.

**4. Recent Earnings & Forecast:**

| Date        | EPS    | Revenue       |
|-------------|--------|----------------|
| 2024-08-05 | 2.15   | $16.11 B      |
| 2024-05-03 | 1.88   | $15.78 B      |
| 2023-11-03 | 1.87   | $15.96 B      |
| 2023-08-07 | -2.35  | $15.04 B      |
| 2024-08-05 | -2.35  | $15.04 B      |

The most recent earnings (2024-08-05) reported EPS of $2.15, exceeding analyst expectations. The company continues to show consistent revenue growth, but EPS has been fluctuating in recent quarters.

**5. News and Recent Issues:**

* **Recent Market Outlook:**  MRK's stock price has been under pressure due to concerns around competition in the pharmaceutical market and uncertainty regarding upcoming drug approvals.
* **Analyst Opinions:** Analyst opinions are mixed. While some analysts remain bullish on MRK's long-term potential, others have expressed concern about its near-term performance.
* **Performance Highlights:**  MRK's key growth drivers include its blockbuster drugs, strong pipeline, and expanding presence in emerging markets. However, the company faces challenges such as increasing generic competition and rising research and development costs.

**6. Summary:**

MRK has underperformed the S&P 500 in recent years, although it is currently showing signs of a possible short-term downtrend. The company's earnings are currently exceeding expectations, but the pharmaceutical market is becoming increasingly competitive. The outlook for MRK remains uncertain, with analysts offering mixed opinions. Investors should carefully monitor the company's upcoming drug approvals and its ability to compete in the market. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. 
